KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to $392.6 million.

  • Resmed's Net Income towards Common Stockholders rose 1391.99% to $392.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.5 billion, marking a year-over-year increase of 1899.33%. This contributed to the annual value of $1.4 billion for FY2025, which is 3719.79% up from last year.
  • As of Q4 2025, Resmed's Net Income towards Common Stockholders stood at $392.6 million, which was up 1391.99% from $348.5 million recorded in Q3 2025.
  • In the past 5 years, Resmed's Net Income towards Common Stockholders ranged from a high of $392.6 million in Q4 2025 and a low of -$78.5 million during Q1 2021
  • For the 5-year period, Resmed's Net Income towards Common Stockholders averaged around $247.8 million, with its median value being $227.3 million (2022).
  • As far as peak fluctuations go, Resmed's Net Income towards Common Stockholders plummeted by 14810.74% in 2021, and later skyrocketed by 32809.6% in 2022.
  • Over the past 5 years, Resmed's Net Income towards Common Stockholders (Quarter) stood at $201.8 million in 2021, then increased by 11.48% to $224.9 million in 2022, then decreased by 7.16% to $208.8 million in 2023, then soared by 65.05% to $344.6 million in 2024, then rose by 13.92% to $392.6 million in 2025.
  • Its Net Income towards Common Stockholders stands at $392.6 million for Q4 2025, versus $348.5 million for Q3 2025 and $379.7 million for Q2 2025.